A Study of Modified mRNA Vaccines in Healthy Adults
Completed · Phase 1 · NCT05397223
Conditions: SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
At a glance
- Research payments reported, 2025
- $568,472
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 308
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1273 (biological), mRNA-1010 (biological), mRNA-1345 (biological), FLUAD® (biological), mRNA-1647 (biological)
- Dates
- Started 2022-05-24; completion 2026-02-27
- Results posted
- Not yet
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
From ClinicalTrials.gov, last updated 2026-03-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $568,472 in research payments for this study in 2025 (51 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nelia E. Sanchez-crespo, M.D. Internal Medicine · Hollywood, FL
- Carlos A. Fierro, MD General Practice · Kansas City, KS
- Bonnie E. Colville, D.O. Family Medicine · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Johnson County Clintrials LLC $352,450
- Texas Center for Drug Development Inc $189,912
- Research Centers of America LLC $26,110
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.